

Resource Summary Report

Generated by [dkNET](#) on Sep 21, 2026

CD138-VioBlue, human

RRID:AB_2655034

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-098-202, RRID:AB_2655034

Antibody Information

URL: http://antibodyregistry.org/AB_2655034

Proper Citation: Miltenyi Biotec Cat# 130-098-202, RRID:AB_2655034

Target Antigen: CD138

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2-2019; Target Distribution B cells, breast, endothelial cells, epithelial cells, neurons, plasma cells, smooth muscle; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-843. (RRID:AB_2751882).

Antibody Name: CD138-VioBlue, human

Description: This monoclonal targets CD138

Target Organism: human

Clone ID: 44F9

Antibody ID: AB_2655034

Vendor: Miltenyi Biotec

Catalog Number: 130-098-202

Record Creation Time: 20231110T034437+0000

Record Last Update: 20260829T190509+0000

Ratings and Alerts

No rating or validation information has been found for CD138-VioBlue, human.

Warning: Discontinued: 2021

Discontinued: 2-2019; Target Distribution B cells, breast, endothelial cells, epithelial cells, neurons, plasma cells, smooth muscle; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-843. (RRID:AB_2751882).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell stem cell, 28(4), 623.